广誉远中药股份有限公司 独立董事 2024 年度述职报告 独立董事：李先荣 本人李先荣，作为广誉远中药股份有限公司（以下简称"公司"）第八届董 事会独立董事，2024 年度严格按照《公司法》《证券法》《上市公司治理准则》《上 市公司独立董事管理办法》等有关法律法规、规范性文件以及《公司章程》《公 司独立董事制度》的规定和要求，本着独立、客观、公正的原则，诚实、勤勉、 独立地履行职责，全面关注公司发展状况，及时了解公司经营情况和财务状况， 认真参加股东大会、董事会及相关专业委员会，积极维护公司整体利益和全体股 东特别是中小股东的合法权益。现就本人 2024 年度的履职情况报告如下： 一、独立董事的基本情况 （一）独立董事个人基本情况 李先荣：北京大学药学专业，本科学历。曾任山西省中医药研究院主任药师、 教授、副院长、享受国务院政府特殊津贴专家，中央组织部和山西省委直接联系 的高级专家。现任山西健硕食品药品研究院研究员、广誉远中药股份有限公司独 立董事。 （二）独立性说明 1、作为公司的独立董事，本人及直系亲属、主要社会关系未在公司或其附 属企业任职；本人及直系亲属没有直接或间接持有公司已发行股份的 1%以上， ...

广誉远中药股份有限公司 独立董事 2024 年度述职报告 独立董事：赵选民 本人赵选民，作为广誉远中药股份有限公司（以下简称"公司"）第八届董 事会独立董事，2024 年度严格按照《公司法》《证券法》《上市公司治理准则》《上 市公司独立董事管理办法》等有关法律法规、规范性文件以及《公司章程》《公 司独立董事制度》的规定和要求，本着独立、客观、公正的原则，诚实、勤勉、 独立地履行职责，全面关注公司发展状况，及时了解公司经营情况和财务状况， 认真参加股东大会、董事会及相关专业委员会，积极维护公司整体利益和全体股 东特别是中小股东的合法权益。现就本人 2024 年度的履职情况报告如下： 一、独立董事的基本情况 （一）独立董事个人基本情况 赵选民：西北农林科技大学管理学博士，注册会计师，会计司法鉴定师，西 安石油大学会计学教授、硕士生导师。曾任瑞泰科技股份有限公司独立董事、陕 西会计学会副会长、西安会计学会副会长、西安培华学院会计与金融学院院长、 西安石油大佳润实业有限公司董事长；现任成都千嘉科技股份有限公司独立董事、 广誉远中药股份有限公司独立董事。 （二）独立性说明 1、作为公司的独立董事，本人及直系亲属、主要社 ...

Financial Performance - The company reported a net profit attributable to shareholders of 74.453 million yuan for the year 2024, with a cumulative undistributed profit of -677.6689 million yuan, resulting in no profit distribution for the year[7]. - The operating revenue for 2024 was CNY 1.221 billion, representing a year-on-year decrease of 4.87%[27]. - The net profit attributable to shareholders for 2024 was CNY 74.45 million, down 17.35% compared to the previous year[27]. - The basic earnings per share for 2024 were CNY 0.15, a decrease of 16.67% from CNY 0.18 in 2023[26]. - The weighted average return on equity for 2024 was 4.86%, down 1.33 percentage points from 6.19% in 2023[26]. - The net cash flow from operating activities for 2024 was CNY 112.39 million, a decline of 47.85% compared to CNY 215.50 million in 2023[27]. - The company's total profit for the period was CNY 80.85 million, reflecting a decrease of 19.45% compared to the previous year[82]. - Total profit, net profit, and net profit attributable to shareholders decreased by CNY 19.527 million, CNY 9.2502 million, and CNY 15.6255 million respectively, mainly due to a 4.87% decline in pharmaceutical industrial revenue[85]. - The company reported a total revenue of 421.12 million, with a significant increase in user data and engagement metrics[159]. Regulatory and Compliance Issues - The company received a notice from the China Securities Regulatory Commission regarding an investigation for suspected violations of information disclosure laws, indicating potential regulatory risks[11]. - The company has faced administrative penalties and market bans from the regulatory authority, with fines paid within the stipulated time[12]. - The company received a notice from the China Securities Regulatory Commission (CSRC) on December 28, 2023, regarding an investigation for suspected information disclosure violations[167]. - The company was fined a total of 8 million yuan for violations, with individual fines of 5 million yuan for Zhang Bin, 2.5 million yuan for Fu Shuhong, and 1 million yuan for Wang Junbo, among others[167]. - Zhang Bin received a 10-year ban from the securities market due to the severity of his violations[169]. - The company received disciplinary action from the Shanghai Stock Exchange on April 16, 2024, related to the violations[169]. - The company has maintained compliance with national regulations and has not experienced any non-operational fund occupation by its controlling shareholders[152]. Strategic Initiatives and Development - The company aims to seek breakthroughs and development amid challenges, adhering to the "1541" strategic framework[37]. - The company launched a "Turtle Wine Restructuring" initiative, establishing a wine company to enhance product quality and expand its product matrix[38]. - The company is focusing on the integration of traditional Chinese medicine with modern health management, aligning with national health policies and consumer trends[49]. - The company is actively exploring international markets, with traditional Chinese medicine being promoted in nearly 200 countries, although international revenue remains relatively low[134]. - The company is committed to technological innovation, collaborating with research institutions to develop replicable and profitable research outcomes in traditional Chinese medicine[142]. - The company plans to deepen channel resources and drive growth through a "long-termism" approach, integrating OTC, medical, and business departments to enhance market influence[138]. Research and Development - Research and development expenses increased by 22.98% year-on-year, driven by a focus on technological innovation[83]. - The company has focused on several key R&D projects, including studies on the efficacy of traditional Chinese medicine for acute stroke and aging-related conditions[115]. - The R&D project for the "An Gong Niu Huang Wan" treatment for acute stroke involved an investment of 582.20 million RMB, accounting for 0.48% of operating revenue[119]. - The "Guilingji Capsule" clinical study for delaying vascular aging received an investment of 238.82 million RMB, representing 0.20% of operating revenue[119]. - The company’s R&D investment totaled 3,859.17 million RMB, representing 3.16% of operating revenue, with a year-on-year increase of 22.98%[120]. Market and Competitive Landscape - The competitive landscape of the traditional Chinese medicine industry in 2024 is characterized by "head dominance and differentiated breakthroughs," with major players leveraging brand strength and full industry chain layouts to maintain their leading positions[50]. - The company has a competitive advantage in the market, focusing on the development of traditional Chinese medicine products[107]. - The company is facing significant pressure from raw material price fluctuations, particularly for key ingredients like Niuhuang, Lingyangjiao, Baizhu, and Zanghonghua, which have seen notable price increases[146]. Corporate Governance and Management - The board of directors consists of 6 members, including 3 independent directors, ensuring a balanced governance structure[150]. - The company has implemented a comprehensive internal control system to strengthen risk management and improve operational transparency[150]. - The audit committee, chaired by a professional accountant, oversees both internal and external audits[154]. - The company has established a trial management system for public opinion management as part of its governance improvements[172]. - The company has a structured approach to determining the remuneration of directors and senior management based on performance and market standards[164]. Employee and Organizational Development - The company has established a compensation policy that emphasizes performance orientation, internal fairness, and external competitiveness[185]. - The employee composition includes 560 production staff, 814 sales personnel, 96 technical staff, 89 financial staff, 139 administrative staff, and 37 others[183]. - The company has implemented a training program focusing on employee empowerment and management skills to enhance overall organizational capability[187]. - The company plans to upgrade its E-learning platform to improve training efficiency and knowledge sharing among employees[187]. Shareholder and Financial Policies - The company maintains a cash dividend policy that stipulates at least 10% of the annual distributable profit should be distributed in cash, provided conditions are met[190]. - The company has a policy that requires cash dividends to be prioritized over stock dividends when conditions allow[189]. - The company has established a cash dividend management system to enhance transparency and protect investor rights[188]. - The company has conducted a share buyback, repurchasing 2,508,556 shares for a total expenditure of approximately 51.22 million yuan, intended for an employee stock ownership plan[193]. - The company has not distributed any cash dividends in the last three accounting years[195].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 417,142,535.52, representing a year-on-year increase of 21.48% compared to CNY 343,378,924.32 in the same period last year[4] - Net profit attributable to shareholders for Q1 2025 reached CNY 63,584,343.46, a significant increase of 53.94% from CNY 41,303,613.94 in the previous year[4] - Basic earnings per share for Q1 2025 were CNY 0.1299, reflecting a 53.91% increase compared to CNY 0.0844 in the same period last year[4] - Total operating revenue for Q1 2025 reached ¥417,142,535.52, a 21.5% increase from ¥343,378,924.32 in Q1 2024[19] - Net profit for Q1 2025 was ¥65,626,931.07, representing a 32.3% increase compared to ¥49,621,931.14 in Q1 2024[20] - Basic earnings per share for Q1 2025 were ¥0.1299, compared to ¥0.0844 in Q1 2024, reflecting a 53.8% increase[20] - The total profit for Q1 2025 was ¥66,055,996.17, an increase of 22.0% from ¥54,131,619.32 in Q1 2024[20] Asset and Liability Management - The total assets at the end of Q1 2025 were CNY 2,404,203,200.31, which is a 5.64% increase from CNY 2,275,876,460.56 at the end of the previous year[5] - As of March 31, 2025, the total assets of the company amounted to RMB 2,404,203,200.31, an increase from RMB 2,275,876,460.56 as of December 31, 2024, reflecting a growth of approximately 5.64%[16] - The total liabilities of the company increased to RMB 747,865,410.70 from RMB 685,165,602.02, which is an increase of approximately 9.15%[16] - The company's equity attributable to shareholders rose to RMB 1,633,392,676.31 from RMB 1,569,808,332.85, reflecting an increase of about 4.06%[16] Cash Flow and Investments - The company achieved a net cash flow from operating activities of CNY 134,210,822.74, a slight increase of 3.71% from CNY 129,411,721.98 in the same period last year[4] - Cash flow from operating activities for Q1 2025 was ¥134,210,822.74, slightly up from ¥129,411,721.98 in Q1 2024[24] - The company reported a net cash outflow from investing activities of ¥11,177,171.30 in Q1 2025, compared to a net inflow of ¥1,186,457.05 in Q1 2024[25] - The company incurred a total of ¥7,115,779.42 in cash outflows from financing activities in Q1 2025, compared to ¥4,101,183.79 in Q1 2024[25] Operational Strategies - The company has focused on optimizing channel networks, upgrading product structures, and enhancing brand value, which contributed to the performance breakthrough in Q1 2025[7] - The company has strengthened its academic and brand empowerment through collaborations with top research institutions, significantly enhancing brand premium effects[7] - The company is committed to maintaining high-quality standards in its products while implementing cost reduction and efficiency improvement measures[7] - The company has seen significant growth in boutique store recruitment and has deepened its engagement in both existing and untapped markets[7] Shareholder Activities - The controlling shareholder, Shennong Technology Group, plans to increase its stake in the company by investing between RMB 50 million and RMB 100 million within 12 months starting from August 26, 2024[11] - As of March 31, 2025, Shennong Technology Group directly held 74,233,468 shares, representing 15.17% of the total share capital[12] - The company has signed a share transfer agreement with Jinchuan Investment, acquiring 71,508,968 shares, which constitutes 14.61% of the total share capital[12] Financial Ratios and Metrics - The weighted average return on equity increased to 3.97%, up from 2.72% at the end of the previous year, marking a 1.25 percentage point increase[5] - The company's cash and cash equivalents increased significantly to RMB 231,335,599.72 from RMB 116,672,133.81, representing an increase of about 98.00%[14] - Accounts receivable rose to RMB 335,605,882.74 from RMB 281,038,900.81, indicating a growth of approximately 19.39%[14] - Inventory decreased to RMB 715,737,603.64 from RMB 766,947,761.39, showing a decline of about 6.68%[14] - The company's short-term borrowings increased to RMB 33,666,027.60 from RMB 19,948,920.17, marking an increase of approximately 68.67%[15] - Total operating costs for Q1 2025 were ¥350,784,558.96, up 24.7% from ¥281,233,386.82 in Q1 2024[19] - R&D expenses increased to ¥12,335,987.72 in Q1 2025, a 37.5% rise from ¥8,983,874.58 in Q1 2024[19]

公司代码：600771 公司简称：广誉远 广誉远中药股份有限公司 2024年度内部控制评价报告 广誉远中药股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部 ...

广誉远中药股份有限公司 董事会审计委员会对会计师事务所 2024 年度履行监督职责 情况的报告 根据《国有企业、上市公司选聘会计师事务所管理办法》《董事会审计委员 会实施细则》等规定和要求，广誉远中药股份有限公司（以下简称"公司"）董 事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职尽责，现对信永中和 会计师事务所（特殊普通合伙）（以下简称"信永中和"）2024 年度履行监督职 责情况汇报如下： 一、会计师事务所基本情况及聘任程序 （一）会计师事务所基本情况 名称：信永中和会计师事务所（特殊普通合伙） 成立日期：2012 年 3 月 2 日 公司分别于 2024 年 4 月 28 日及 2024 年 6 月 28 日召开董事会审计委员会会 议、第八届董事会第九次会议及 2023 年年度股东大会，审议通过了《关于续聘 2024 年年度财务审计机构暨内部控制审计机构的议案》，同意续聘信永中和为公 司 2024 年度财务报告审计机构和内部控制审计机构。 二、审计委员会对会计师事务所履行审计工作的监督情况 根据公司《董事会审计委员会实施细则》等有关规定，审计委员会对会计师 事务所履行监督职责的情况如下： 组织形式 ...

广誉远中药股份有限公司 | 念うともあり、中国の人気の人気の人の出版は、 + です 求人用 2004 2200 | | | --- | --- | | 8 号富华大厦 A 座 9 层 | telephone: +86 (010) 6554 2288 | | 9/F. Block A. Fu Hua Mansion, | | | No.8, Chaoyangmen Beidajie, ShineWing | | | Donacheng District, Belling, 1454. | +86 (010) 6554 7190 | | certified public accountants 100027, P.R. China | facsimile: +86 (010) 6554 7190 | 关于广誉远中药股份有限公司 2024 年度非经营性资金占用及其他关联资金往来的专项说明 XYZH/2025TYAA2B0208 2024 年度 非经营性资金占用及其他关联资金往来的 专项说明 | 蒙引 | 觉得 | | --- | --- | | 专项说明 | 1-2 | | 非经营性资金占用及其他关联资金往来情况汇 ...

广誉远中药股份有限公司 对 2024 年度会计师事务所履职情况的报告 一、2024 年年审会计师事务所基本情况 首席合伙人：谭小青先生 截止 2024 年 12 月 31 日，信永中和合伙人（股东）259 人，注册会计师 1780 人。签署过证券服务业务审计报告的注册会计师人数超过 700 人。 信永中和 2023 年度业务收入为 40.46 亿元，其中，审计业务收入为 30.15 亿元，证券业务收入为 9.96 亿元。2023 年度，信永中和上市公司年报审计项 目 364 家，收费总额 4.56 亿元，涉及的主要行业包括制造业，信息传输、软件 和信息技术服务业，交通运输、仓储和邮政业，电力、热力、燃气及水生产和 供应业，批发和零售业，采矿业、文化和体育娱乐业，金融业，水利、环境和 公共设施管理业、建筑业等。公司同行业上市公司审计客户家数为 238 家。 （二）聘任会计师事务所履行的程序 根据《国有企业、上市公司选聘会计师事务所管理办法》，公司分别于 2024 年 4 月 28 日及 2024 年 6 月 28 日召开董事会审计委员会会议、第八届董 事会第九次会议及 2023 年年度股东大会，审议通过了《关于 ...

证券代码：600771 证券简称：广誉远 编号：临 2025-006 广誉远中药股份有限公司 关于续聘会计师事务所的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要提示： 一、拟聘任会计师事务所的基本情况 （一）机构信息 1. 基本信息 名称：信永中和会计师事务所（特殊普通合伙） 成立日期：2012 年 3 月 2 日 组织形式：特殊普通合伙企业 注册地址：北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层 首席合伙人：谭小青先生 截至 2024 年 12 月 31 日，信永中和合伙人（股东）259 人，注册会计师 1780 人。 签署过证券服务业务审计报告的注册会计师人数超过 700 人。 信永中和 2023 年度业务收入为 40.46 亿元，其中，审计业务收入为 30.15 亿元， 证券业务收入为 9.96 亿元。2023 年度，信永中和上市公司年报审计项目 364 家，收费 总额 4.56 亿元，涉及的主要行业包括制造业，信息传输、软件和信息技术服务业，交 通运输、仓储和邮政业，电力、热力、燃气 ...

广誉远中药股份有限公司 关于 2024 年度计提信用减值损失和资产减值损失的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广誉远中药股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日分别召开第八 届董事会第十四次会议及第八届监事会第十一次会议，审议通过了《关于 2024 年度计 提信用减值损失和资产减值损失的议案》。本次计提资产减值准备的具体情况如下： 一、本次计提信用减值损失和资产减值损失情况概述 单位：万元 证券代码：600771 证券简称：广誉远 编号：临 2025-005 | | 项目 | 本期发生额（收益以"－"填列） | | --- | --- | --- | | 信用减值损失 | 应收账款坏账损失 | 6,936.27 | | | 其他应收款坏账损失 | 65.20 | | | 小计 | 7,001.47 | | 资产减值损失 | 存货跌价损失 | 745.41 | | | 固定资产减值损失 | 268.75 | | | 其他非流动资产减值准备 | 202.31 | | | 小计 ...